Clinigen Group

Clinigen Group is a rapidly-growing specialty pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time to improve the quality of people’s lives around the world. The Group consists of four synergistic businesses that provide medicines to patients with unmet need through clinical trials, licensed and unlicensed routes: Clinigen Clinical Trial Services (CTS) - The global leader in the specialist supply and management of quality-assured comparator drugs and other commercial medicines for patients in clinical trials. Cinigen is also the leading global patient access specialist working to provide ethical and compliant access to unlicensed medicines for healthcare providers and their patients with high unmet medical need: Idis Managed Access (MA) - Ethically manages early access to unlicensed investigational medicines on behalf of pharmaceutical and biotech companies. Idis Global Access (GA) - Enables access to post-approved medicines in regions where they are not commercially available but where there is a patient need. Clinigen Specialty Pharmaceuticals (SP) - Revitalizes essential hospital only medicines ensuring continuity of supply to hospital pharmacists, doctors and patients.
Company Growth (employees)
Type
Public
HQ
Burton Upon Trent, GB
Founded
2010
Size (employees)
465 (est)+200%
Clinigen Group was founded in 2010 and is headquartered in Burton upon Trent, GB

Clinigen Group Office Locations

Clinigen Group has an office in Burton upon Trent
Burton Upon Trent, GB (HQ)
Clinigen, Pitcairn House, Crown Square, First Avenue

Clinigen Group Metrics

Clinigen Group Financial Metrics

Clinigen Group's revenue was reported to be £339.9 m in FY, 2016 which is a 84% increase from the previous period.

Revenue (FY, 2016)

£339.9 m

Revenue growth (FY, 2015 - FY, 2016), %

84%

Gross profit (FY, 2016)

£96.1 m

Gross profit margin (FY, 2016), %

28%

Net income (FY, 2016)

£13.5 m

Market capitalization (22-May-2017)

£981.8 m

Closing share price (22-May-2017)

£8.6

Cash (30-Jun-2016)

£27.8 m
Clinigen Group's current market capitalization is £981.8 m.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

£122.6 m£126.6 m£184.4 m£339.9 m

Revenue growth, %

3%46%84%

Cost of goods sold

£87.5 m£85.4 m£130.7 m£243.8 m

Gross profit

£35.1 m£41.2 m£53.7 m£96.1 m

Gross profit Margin, %

29%33%29%28%

Operating expense total

£20.5 m£19.7 m£44.5 m

Pre tax profit

£21.3 m£8.3 m£15.9 m

Net Income

£16.2 m£5.7 m£13.5 m
FY, 2014FY, 2015FY, 2016

Cash

£21.8 m£27.8 m£27.8 m

Accounts Receivable

£20.2 m£51.4 m£57.6 m

Current Assets

£51.4 m£110 m£112.6 m

PP&E

£2.9 m£6.6 m£13.6 m

Goodwill

£50.5 m£302.5 m£333.7 m

Total Assets

£104.9 m£419.1 m£459.9 m

Accounts Payable

£10.3 m£48.1 m£68.6 m

Current Liabilities

£38.6 m£158.4 m£164.3 m

Retained Earnings

£13.7 m£3.1 m£9.4 m

Total Equity

£66.3 m£204.6 m£236.5 m

Financial Leverage

1.6 x2 x1.9 x
FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

£19.3 m£13.1 m£42.1 m

Cash From Financing Activities

£13.8 m£181.3 m(£12.3 m)

Income Taxes Paid

(£5.1 m)(£2.6 m)(£2.4 m)
Y, 2016

Financial Leverage

1.9 x

Clinigen Group Operating Metrics

FY, 2016

Countries

43

Units Shipped

3.97 m

Clinigen Group Market Value History

Clinigen Group Revenue Breakdown

Clinigen Group Online Presence

Clinigen Group News

Clinigen Group Company Life

You may also be interested in